CN114686422A - 硫酸化甘露葡萄糖醛酸六糖在诱导性多能干细胞定向分化为心肌细胞中的应用 - Google Patents
硫酸化甘露葡萄糖醛酸六糖在诱导性多能干细胞定向分化为心肌细胞中的应用 Download PDFInfo
- Publication number
- CN114686422A CN114686422A CN202210227579.XA CN202210227579A CN114686422A CN 114686422 A CN114686422 A CN 114686422A CN 202210227579 A CN202210227579 A CN 202210227579A CN 114686422 A CN114686422 A CN 114686422A
- Authority
- CN
- China
- Prior art keywords
- sulfated
- cells
- gm6s1
- differentiation
- pluripotent stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004069 differentiation Effects 0.000 title claims abstract description 38
- 210000004027 cell Anatomy 0.000 title claims abstract description 34
- 210000004263 induced pluripotent stem cell Anatomy 0.000 title claims abstract description 24
- 230000002107 myocardial effect Effects 0.000 title claims abstract description 20
- 239000002253 acid Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229930182480 glucuronide Natural products 0.000 claims 3
- 150000008134 glucuronides Chemical class 0.000 claims 3
- 210000004413 cardiac myocyte Anatomy 0.000 abstract description 16
- 210000000130 stem cell Anatomy 0.000 abstract description 9
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 210000004165 myocardium Anatomy 0.000 abstract description 4
- 230000006698 induction Effects 0.000 description 31
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 11
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 5
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 5
- 239000007640 basal medium Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 239000005717 Laminarin Substances 0.000 description 2
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910006069 SO3H Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101150114527 Nkx2-5 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210227579.XA CN114686422B (zh) | 2022-03-08 | 2022-03-08 | 硫酸化甘露葡萄糖醛酸六糖在诱导性多能干细胞定向分化为心肌细胞中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210227579.XA CN114686422B (zh) | 2022-03-08 | 2022-03-08 | 硫酸化甘露葡萄糖醛酸六糖在诱导性多能干细胞定向分化为心肌细胞中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114686422A true CN114686422A (zh) | 2022-07-01 |
CN114686422B CN114686422B (zh) | 2024-03-05 |
Family
ID=82137663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210227579.XA Active CN114686422B (zh) | 2022-03-08 | 2022-03-08 | 硫酸化甘露葡萄糖醛酸六糖在诱导性多能干细胞定向分化为心肌细胞中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114686422B (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090004150A1 (en) * | 2004-03-31 | 2009-01-01 | Reinhard Schwartz-Albiez | Method for Expanding Postembryonic Stem and Progenitor Cells from Umbilical Cord Blood and Immunotherapeutic Agent |
CN103539863A (zh) * | 2012-07-12 | 2014-01-29 | 中国科学院海洋研究所 | 褐藻来源的富含葡萄糖醛酸的低硫酸化杂聚糖在制备治疗帕金森病药物和保健品中的应用 |
CN108060125A (zh) * | 2018-02-07 | 2018-05-22 | 苏州大学 | 促进多能干细胞分化为心肌细胞成熟的方法 |
CN108392485A (zh) * | 2018-01-17 | 2018-08-14 | 浙江工业大学 | 硫酸化甘露葡萄糖醛酸寡糖在制备治疗或预防神经退行性疾病药物或保健品中的应用 |
CN110917208A (zh) * | 2019-12-27 | 2020-03-27 | 浙江医院 | 硫酸化甘露葡萄糖醛酸六糖在防治动脉粥样硬化中的应用 |
CN111187750A (zh) * | 2020-01-17 | 2020-05-22 | 复旦大学附属中山医院 | 生物胺诱导多功能干细胞向心肌细胞分化的方法与应用 |
CN111249288A (zh) * | 2019-12-27 | 2020-06-09 | 浙江医院 | 甘露葡萄糖醛酸寡糖及其衍生物在制备治疗和/或预防hcmv药物中的应用 |
US20210017562A1 (en) * | 2018-03-23 | 2021-01-21 | The Brigham And Women's Hospital | Compositions and methods for enforcing fucosylation of lactosaminyl glycans in human cells with alpha(1,3)-fucosyltransferases |
CN112870217A (zh) * | 2021-02-10 | 2021-06-01 | 浙江工业大学 | 甘露葡萄糖醛酸多(寡)糖及其硫酸化衍生物在制备治疗骨质疏松症药物中的应用 |
-
2022
- 2022-03-08 CN CN202210227579.XA patent/CN114686422B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090004150A1 (en) * | 2004-03-31 | 2009-01-01 | Reinhard Schwartz-Albiez | Method for Expanding Postembryonic Stem and Progenitor Cells from Umbilical Cord Blood and Immunotherapeutic Agent |
CN103539863A (zh) * | 2012-07-12 | 2014-01-29 | 中国科学院海洋研究所 | 褐藻来源的富含葡萄糖醛酸的低硫酸化杂聚糖在制备治疗帕金森病药物和保健品中的应用 |
CN108392485A (zh) * | 2018-01-17 | 2018-08-14 | 浙江工业大学 | 硫酸化甘露葡萄糖醛酸寡糖在制备治疗或预防神经退行性疾病药物或保健品中的应用 |
CN108060125A (zh) * | 2018-02-07 | 2018-05-22 | 苏州大学 | 促进多能干细胞分化为心肌细胞成熟的方法 |
US20210017562A1 (en) * | 2018-03-23 | 2021-01-21 | The Brigham And Women's Hospital | Compositions and methods for enforcing fucosylation of lactosaminyl glycans in human cells with alpha(1,3)-fucosyltransferases |
CN110917208A (zh) * | 2019-12-27 | 2020-03-27 | 浙江医院 | 硫酸化甘露葡萄糖醛酸六糖在防治动脉粥样硬化中的应用 |
CN111249288A (zh) * | 2019-12-27 | 2020-06-09 | 浙江医院 | 甘露葡萄糖醛酸寡糖及其衍生物在制备治疗和/或预防hcmv药物中的应用 |
CN111187750A (zh) * | 2020-01-17 | 2020-05-22 | 复旦大学附属中山医院 | 生物胺诱导多功能干细胞向心肌细胞分化的方法与应用 |
CN112870217A (zh) * | 2021-02-10 | 2021-06-01 | 浙江工业大学 | 甘露葡萄糖醛酸多(寡)糖及其硫酸化衍生物在制备治疗骨质疏松症药物中的应用 |
Non-Patent Citations (2)
Title |
---|
安子哲等: "褐藻来源硫酸岩藻聚糖的化学组成与结构的研究进展", 中国海洋药物, vol. 40, no. 04, pages 50 - 63 * |
耿丽华: "海带多糖酸解产物的分离分析及免疫调节作用研究", 中国博士学位论文全文数据库, no. 12, pages 079 - 13 * |
Also Published As
Publication number | Publication date |
---|---|
CN114686422B (zh) | 2024-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108359636B (zh) | 一种提高多能干细胞定向分化为心肌细胞的诱导方法 | |
CN102485885A (zh) | 脂肪干细胞的分离方法和用途 | |
CN114317421B (zh) | 强化间充质干细胞促进血管生成的方法、组合物及应用 | |
CN101831403B (zh) | 体外扩增人脐带胎盘间充质干细胞的方法 | |
CN109294980B (zh) | 红景天及红景天苷在干细胞定向分化为心肌样细胞中的应用 | |
CN109112109A (zh) | 一种骨髓间充质干细胞外泌体的改造方法 | |
CN111759862A (zh) | 干细胞外泌体在制备抗结肠炎恶化药物中的应用 | |
CN111973632A (zh) | 一种用于治疗糖尿病的干细胞制剂及其制备方法 | |
CN113559273B (zh) | 一种静脉注射用成体干细胞的预处理方法、成体干细胞注射液及应用 | |
AU2020103625A4 (en) | Applications of bacillus calmette-guerin (bcg) polysaccharide and nucleic acid in in-vitro culture of cytokine-induced-killer (cik) cells and preparation of antitumor drugs | |
CN106606512B (zh) | 一种用于治疗心肌梗死的混合细胞制剂及制备方法与应用 | |
CN114686422B (zh) | 硫酸化甘露葡萄糖醛酸六糖在诱导性多能干细胞定向分化为心肌细胞中的应用 | |
CN104611291B (zh) | 一种用于将胚胎干细胞诱导为心肌细胞的培养基及其应用 | |
CN106701669A (zh) | 临床治疗用间充质干细胞及其制备方法和用途 | |
CN115478050B (zh) | 一种提高干细胞体外扩增能力的方法 | |
CN1746297A (zh) | 胎盘来源间充质干细胞及其制备 | |
CN108034634B (zh) | 一种从经血中分离宫内膜间充质干细胞的方法 | |
CN113201491B (zh) | 一种促进干细胞体外增殖和分化的培养方法 | |
CN110592010B (zh) | 积雪草酸用于促进人脂肪间充质干细胞体外增殖并诱导其成软骨分化的用途 | |
CN110592009B (zh) | 一种积雪草酸衍生物用于促进人脂肪间充质干细胞体外增殖并维持干性的用途 | |
CN102119936B (zh) | 制备利用人羊膜间充质细胞治疗缺血性脑损伤注射液的方法及其注射液 | |
CN1410531A (zh) | 一种人外周血血管内皮祖细胞的培养方法 | |
CN113801843B (zh) | 一种增强人尿源性干细胞干性的方法 | |
CN111087442B (zh) | 一种多肽提取方法 | |
CN111718898B (zh) | 提高滑膜间充质干细胞逆境耐受性的方法及其试剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Mao Genxiang Inventor after: Xu Xiaogang Inventor after: Jin Weihua Inventor after: Wan Xiaoqing Inventor after: Lin Ping Inventor after: Zhao Zhenlei Inventor after: Wang Sanying Inventor after: Zhou Xuqiang Inventor after: Jiang Di Inventor before: Xu Xiaogang Inventor before: Mao Genxiang Inventor before: Jin Weihua Inventor before: Wan Xiaoqing Inventor before: Lin Ping Inventor before: Zhao Zhenlei Inventor before: Wang Sanying Inventor before: Zhou Xuqiang Inventor before: Jiang Di |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |